Image Source: Zacks Investment Research Spikevax, targeting the variant JN.1., is currently approved in the United States, the United Kingdom, Japan and Taiwan. Last month, the FDA approved ...

CAMBRIDGE, MA - Moderna , Inc. (NASDAQ:MRNA) is on the brink of securing European Union approval for the latest version of its COVID-19 vaccine, Spikevax, which targets the SARS-CoV-2 variant JN.1.

In other recent news, Moderna's updated COVID-19 vaccine, Spikevax, has received approval from the UK's Medicines and Healthcare products Regulatory Agency, targeting the JN.1 variant. This move ...

The endorsement comes as Moderna's updated Spikevax COVID-19 vaccine formulation, targeting the JN.1 variant, received approval from the Taiwan Food & Drug Administration. This follows recent ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted Moderna COVID-19 vaccine (Spikevax) that targets the JN.1 COVID-19 subvariant. This vaccine is licensed for ...

The endorsement comes as Moderna's updated Spikevax COVID-19 vaccine formulation, targeting the JN.1 variant, received approval from the Taiwan Food & Drug Administration. This follows recent ...